Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Nadia Harbeck(Breast Center), Étienne Brain(Institut Curie), Matteo Puntoni(University of Parma), Rachel Wuerstlein(LMU Klinikum), Michela Palleschi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Javier Cortés(Villa Maria Hospital), Oriana Nanni(National Institutes of Health), Valentina Rossi(Istituto Oncologico Veneto), Arnoldo Piccardo(Ente Ospedaliero Ospedali Galliera), Federica Matteucci(Ospedale G.B. Morgagni - L.Pierantoni), Simone Nardin(Ospedale Policlinico San Martino), Antonio Frassoldati(Italian Oncology Group of Clinical Research), B. Ruffilli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Boni(Ospedale Policlinico San Martino), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jean‐Louis Alberini, Manuela Monti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea De Censi(Ente Ospedaliero Ospedali Galliera), Harun Ilhan(Ludwig-Maximilians-Universität München)
Cited by 2
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k